Testing new drugs for heart failure in children

Pediatric Critical Care Medicine

Volumn 7, Issue 5, 2006, Pages 493-494

  Wessel, David L ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Catecholamines; Congenital heart disease; Levosimendan; Low cardiac output syndrome; Milrinone

Indexed keywords

CATECHOLAMINE DERIVATIVE; DOBUTAMINE; DOPAMINE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; PHOSPHODIESTERASE III INHIBITOR;

ARTERY PERFUSION; CHILD; CHILD HOSPITALIZATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEART AFTERLOAD; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HIGH RISK PATIENT; HUMAN; MYOCARDITIS; NEWBORN; NEWBORN INTENSIVE CARE; PRIORITY JOURNAL; SEPTIC SHOCK; SIDE EFFECT; TACHYCARDIA;

ADOLESCENT; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CATECHOLAMINES; CHILD; CHILD, PRESCHOOL; HUMANS; HYDRAZONES; INFANT; MILRINONE; PYRIDAZINES;

EID: 33748671155     PISSN: 15297535     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.PCC.0000235664.22923.67     Document Type: Editorial

References (12)

1. Wessel DL: Managing low cardiac output syndrome after congenital heart surgery. Crit Care Med 2001; 29:S220-S230
2. Caspi J, Coles JG, Benson LN, et al: Age-related response to epinephrine-induced myocardial stress. A functional and ultrastructural study. Circulation 1991; 84(suppl III):III-394-III-399
3. Caspi J, Coles JG, Benson LN, et al: Effects of high plasma epinephrine and Ca2+ concentrations on neonatal myocardial function after ischemia. J Thorac Cardiovasc Surg 1993; 105:59-67
4. Hoffman TM, Wernovsky G, Atz AM, et al: Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 2003; 107:996-1002
5. Slawsky MT, Colucci WS, Gottlieb SS, et al: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators. Circulation 2000; 102:2222-2227
6. Adamopoulos S, Parissis J, Iliodromitis EK, et al: Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98:102-106
7. Follath F, Cleland JGF, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002; 360:196
8. Turanlahti M, Boldt T, Palkama T, et al: Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med 2004; 5:457-462
9. Egan JR, Clarke AJB, Williams S, et al: Levosimendan for low cardiac output: A pediatric experience. J Intensive Care Med 2006; 21:183-187
10. Namachivayam P, Crossland DS, Butt WW, et al: Early experience with Levosimendan in children with ventricular dysfunction. Pediatr Crit Care Med 2006; 7:445-448
11. Department of Health and Human Services: U.S. Food and Drug Administration Center for Drug Evaluation and Research. Available at: http://www.fda.gov/cder/pediatric/. Accessed June 22, 2006
12. Shaddy RE: Drug trials in pediatric heart failure: Hype or improved clinical science? Future Cardiol 2006; 2:281-286